JAZZ PHARMACEUTICALS INC

Form 4 June 06, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

OMB APPROVAL

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * TANANBAUM JAMES B

(First)

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

Symbol JAZZ PHARMACEUTICALS INC

(Check all applicable)

[JAZZ]

(Last)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

_X__ Director Officer (give title

10% Owner _ Other (specify

C/O PROSPECT VENTURE PARTNERS, 435 TASSO ST.,

SUITE 200

(Street) 4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

06/06/2007

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

PALO ALTO, CA 94301

(City)	(State)	(Zip) Tabl	e I - Non-I	Derivative So	ecurit	ies Acq	uired, Disposed	of, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securitie or(A) or Disp (Instr. 3, 4 a	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/06/2007		Code V	Amount 660,849	(D)	Price (1)	(Instr. 3 and 4) 660,849	I	By Prospect Venture Partners II, L.P. (2)
Common Stock	06/06/2007		C	10,063	A	(1)	10,063	I	By Prospect Associates II, L.P. (3)
Common Stock	06/06/2007		С	554,801	A	<u>(1)</u>	554,801	I	By Prospect Venture Partners II,

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock A Preferred Stock	<u>(1)</u>	06/06/2007		С	660,849	<u>(1)</u>	<u>(1)</u>	Common Stock	660,849
Stock A Preferred Stock	(1)	06/06/2007		С	10,063	<u>(1)</u>	<u>(1)</u>	Common Stock	10,063
Stock B Preferred Stock	(1)	06/06/2007		С	554,801	<u>(1)</u>	<u>(1)</u>	Common Stock	554,801
Stock B Preferred Stock	(1)	06/06/2007		C	8,448	<u>(1)</u>	<u>(1)</u>	Common Stock	8,448

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			

Reporting Owners 2

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 4

TANANBAUM JAMES B
C/O PROSPECT VENTURE PARTNERS
435 TASSO ST., SUITE 200
PALO ALTO, CA 94301

Signatures

/s/ Dave Markland, Attorney in Fact for James B. Tananbaum, M.D.

06/06/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Issuer's Preferred Stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The shares are owned by Prospect Venture Partners II, L.P. ("PVP II"), which is under common control with Prospect Associates II, L.P. ("PA II"). Prospect Management Co. II, L.L.C. ("PMC II") serves as the sole general partner of PVP II. James B. Tananbaum, M.D. is a Managing Director of PMC II and shares voting and investment power over the shares held by PVP II. The Reporting Person disclaims beneficial ownership of the shares held by PVP II except to the extent of his proportionate pecuniary interest therein.
- The shares are owned by PA II. PMC II serves as the sole general partner of PA II. James B. Tananbaum, M.D. is a Managing Director of (3) PMC II and shares voting and investment power over the shares held by PA II. The Reporting Person disclaims beneficial ownership of the shares held by PA II except to the extent of his proportionate pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3